Literature DB >> 2882981

Urinary excretion kinetics of famotidine in rats.

J H Lin, L E Los, E H Ulm, D E Duggan.   

Abstract

Famotidine is a new histamine H2-receptor antagonist which has been demonstrated to be more potent than cimetidine and ranitidine in inhibiting gastric acid secretion. Nine groups of adult male Sprague-Dawley rats received an ia injection of various loading doses of famotidine followed immediately by a constant infusion of the drug at different rates for 6 hr. When steady state famotidine concentrations in plasma were low, renal clearance of the drug (CLR) was greater than glomerular filtration (GFR), and the ratio CLR/GFR was about 4.5 at plasma concentrations of 0.2-1.8 micrograms/ml, suggesting that famotidine was actively secreted by the renal tubules. The CLR decreased as famotidine concentration in plasma increased, and the ratio CLR/GFR approached 1 in the concentration range of 25-76 micrograms/ml, thus providing evidence for saturation of the secretory mechanism. The maximum rate of secretory transport (Tm) of famotidine averaged 180 micrograms/min/kg. On average, some 50-70% of an ia bolus dose was excreted in the urine as unchanged drug within 24 hr of administration. Over the dose range of 0.3-30 mg/kg famotidine, there was no dose-dependent effect on total or renal clearance. Since the lowest dose level, 0.3 mg/kg, is below the recommended human therapeutic dose for famotidine (0.6 mg/kg), the saturation of the renal excretion process observed here in rats is not likely to be of clinical significance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2882981

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

3.  Effects of antacids and food on absorption of famotidine.

Authors:  J H Lin; A N Chremos; S M Kanovsky; S Schwartz; K C Yeh; J Kann
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 5.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

Review 6.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.